Rocket Pharmaceuticals Completes $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals (NASDAQ: RCKT) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million,... Read More

The post Rocket Pharmaceuticals Completes $180 Million Sale of Priority Review Voucher appeared first on citybiz.